On August 29, 2024, Safety Shot, Inc., a Delaware-based wellness company, announced groundbreaking clinical trial results for its product, Safety Shot, which is designed to reduce blood alcohol content and alleviate symptoms associated with excessive drinking. The double-blind, randomized, placebo-controlled study demonstrated a significant increase in aldehyde dehydrogenase activity and a decrease in acetaldehyde levels, leading to a rapid reduction in blood alcohol content and associated toxins within 30 minutes. The company's COO and Co-Inventor, David Sandler, highlighted the product's unique patented formula and its ability to preemptively address the negative effects of heavy alcohol consumption. Safety Shot, Inc. is expanding its product line, which includes a 12oz drink, 4oz shot, and dry powder stick pack, and is introducing business-to-business sales throughout 2024. The press release also contained forward-looking statements regarding the product's development and commercialization, as well as the company's compliance with laws and potential risks as detailed in its SEC filings.

On August 29, 2024, Safety Shot, Inc., a Delaware-based wellness company, announced groundbreaking clinical trial results for its product, Safety Shot, which is designed to reduce blood alcohol content and alleviate symptoms associated with excessive drinking. The double-blind, randomized, placebo-controlled study demonstrated a significant increase in aldehyde dehydrogenase activity and a decrease in acetaldehyde levels, leading to a rapid reduction in blood alcohol content and associated toxins within 30 minutes. The company's COO and Co-Inventor, David Sandler, highlighted the product's unique patented formula and its ability to preemptively address the negative effects of heavy alcohol consumption. Safety Shot, Inc. is expanding its product line, which includes a 12oz drink, 4oz shot, and dry powder stick pack, and is introducing business-to-business sales throughout 2024. The press release also contained forward-looking statements regarding the product's development and commercialization, as well as the company's compliance with laws and potential risks as detailed in its SEC filings.